Background: The biodistribution of liposomal ICG and the optimal clinical strategy for PDT using liposomal ICG is unclear because of the lack of clinical evidences.
Purpose: This case-series study aimed to evaluate the biodistribution of liposomal ICG in patients with breast cancer undergoing PDT.
Method and result: Four patients with breast cancer underwent PDT with liposomal ICG in addition to a transcatheter arterial chemoembolization(TACE)from August 2020 to October 2020. Patients were administered 300 mg liposomal ICG(180 mg intravenously and 120 mg intratumorally via the feeding artery) 24 hours before PDT during a TACE procedure. We used near-infrared fluorescence(NIR)imaging system(LIGHTVISION®; Shimadzu Corporation)to detect the biodistribution of liposomal ICG. The peak intratumoral liposomal ICG uptake was shown 24 hours after liposomal ICG administration in 3 patients. Only 1 patient had peak uptake at 6 hours, with no uptake at 24 hours.
Conclusion: NIR-imaging system may be and adjuvant in evaluation of liposomal ICG biodistribution in patients with breast cancer and assisting in the decision-making for the use of PDT with liposomal ICG.